EGFR

EGFR Related Products (735):

By Effects:	Inhibitors (573) Agonists (2) Antagonist (1) Activators (5) Modulators (3) Chemicals (2) Inducers (3) Degraders (19) Controls (5) Substrate (1) Ligands (9)

Cat. No.	Product Name	Effect	Purity

HY-183310

EGFR-IN-210	Inhibitor
EGFR-IN-210 is a EGFR kinase inhibitor with an IC₅₀ of 0.198 μM. EGFR-IN-210 induces antiproliferative, pro-apoptotic, G0/G1 cell cycle arrest, DNA synthesis inhibition and anti-migratory effects in cancer cells. EGFR-IN-210 can be used for the research of various cancers including colorectal cancer.

HY-173619

EGFR-IN-160	Inhibitor
EGFR-IN-160 (Compound R12) is an EGFR inhibitor (IC₅₀ values are 1.62, 0.49 and 0.98 μM for EGFR^WT, EGFR^T790M and EGFR^{L858R/T790M/C797S}, respectively). EGFR-IN-160 induces G2/M and S phase arrest and apoptosis in NCI-H522 cells, and has anticancer activity. EGFR-IN-160 has antioxidant effects against DPPH (IC₅₀: 12.11 µM) and H2O2 (IC₅₀: 8.89 µM).

HY-P991572

MM-151	Antagonist
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer.

HY-175173

EGFR-IN-166	Inhibitor
EGFR-IN-166 (Compound 2) is a EGFR inhibitor. EGFR-IN-166 has potent anticancer activity against breast cancer cells with IC₅₀s of 69.63 and 22.84 μM for MCF-7 and MDA-MB-231 cells, respectively. EGFR-IN-166 significantly inhibits cell migration and EGFR expression. EGFR-IN-166 can be used for breast cancer research.

HY-162332

EGFR-PK/JNK-2-IN-1	Inhibitor
EGFR-PK/JNK-2-IN-1 (Compound 6c) is a dual inhibitor of EGFR-PK and JNK-2 with IC₅₀s of 2.7 and 3.0 μM, respectively. EGFR-PK/JNK-2-IN-1 can induce apoptosis and induce cell cycle arrest at different cell phases. EGFR-PK/JNK-2-IN-1 can be used for the research of cancer.

HY-181701

EGFR-IN-202	Inhibitor
EGFR-IN-202 is an epidermal growth factor receptor (EGFR) inhibitor that selectively targets EGFR exon 20 insertion mutations. EGFR-IN-202 can be used in research related to non-small cell lung cancer.

HY-RS04467

Erbb2 Mouse Pre-designed siRNA Set A	Inhibitor
Erbb2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-161145

EGFR/microtubule-IN-1	Inhibitor
EGFR/microtubule-IN-1 (Compound 10c) is a dual inhibitor targeting EGFR and tubulin. The IC₅₀ for inhibiting EGFR is 10.66 nM. EGFR/microtubule-IN-1 can reduce the phosphorylation levels of EGFR, AKT and ERK, hinder tubulin polymerization, and induce apoptosis.

HY-P991985

Anti-Her4 Antibody	Inhibitor
Anti-Her4 Antibody is an anti-Her4 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P10224

G7-18NATE
G7-18NATE is a peptide inhibitor of Grb7. HY-P10224 binds to the Grb7-SH2 domain with micromolar affinity (K_D = 18.1 μM). G7-18NATE inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines.

HY-162881

DS06652923	Inhibitor
DS06652923 is an orally active EGFR triple mutation inhibitor. DS06652923 has a growth inhibition effect on Ba/F3 EGFR del19/T90M/C797S cells, with a GI₅₀ value of 9.4 nM. DS06652923 can lead to tumor regression in Ba/F3 xenograft models.

HY-178313

EGFR ligand-18	Degrader
EGFR ligand-18 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC EGFR degrader 16 (HY-178242). PROTAC EGFR degrader 16 is a potent EGFR PROTAC degrader with anti-tumor activity.

HY-10261AS

Afatinib-d₆ dimaleate	Inhibitor
Afatinib-d₆ (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC₅₀s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

HY-153856A

TAS2940 fumarate	Inhibitor
TAS2940 fumarate is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 fumarate against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC₅₀ values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 fumarate can be used for the study of tumors with HER2 and EGFR aberrations.

HY-144605

PROTAC EGFR degrader 3	Inhibitor
PROTAC EGFR degrader 3 is a potent PROTAC EGFR degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectively. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation.

HY-P992171

ADCT-701 Antibody
ADCT-701 Antibody is a humanized IgG1 antibody against hDLK-1 and an ADC antibody. ADCT-701 Antibody can be conjugated with the PBD dimer cytotoxin SG3199 (HY-101161) via the cleavable Val-Ala (HY-W007035) linker to construct the ADC ADCT-701. ADCT-701 Antibody can be used in the research of neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and rhabdomyosarcoma.

HY-161602

EGFR/HER2-IN-13	Inhibitor
EGFR/HER2-IN-13 (Compd 38) is an inhibitor of mutant EGFR/HER2s which are resistant to other drugs. EGFR/HER2-IN-13 can be used for cancer research.

HY-156639

EGFR/ErbB-2 inhibitor-1	Inhibitor
EGFR/ErbB-2 inhibitor-1 is a ErbB2/HER2 inhibitor.

HY-157432

EGFR-IN-97	Inhibitor
EGFR-IN-97 (compound 6q) is a EGFR inhibitor. EGFR-IN-97 shows inhibitory activity against Ba/F3-EGFR^{L858R/T790M/C797S} and Ba/F3-EGFR^{Del19/T790M/C797S} cells, with IC₅₀ values of 0.42 μM and 0.41 μM, respectively. EGFR-IN-97 can promote apoptosis of NCI-H1975-EGFR^{L858R/T790M/C797S} cells at the concentration of 0.8 μM.

HY-138627B

AST5902 mesylate	Inhibitor
AST5902 mesylate is a principal metabolite of Alflutinib, exhibiting significant antineoplastic activity. AST5902 mesylate contributes to the overall pharmacological effects in the treatment of non-small cell lung cancer. AST5902 mesylate is involved in the response to activating EGFR mutations and can help overcome EGFR T790M drug-resistant mutations.

Name
Email *

	Sorry, but the email address you supplied was invalid.